A Randomized Comparison of a Novel Bioabsorbable Vascular Closure Device Versus Manual Compression in the Achievement of Hemostasis After Percutaneous Femoral Procedures The ECLIPSE (Ensure's Vascular Closure Device Speeds Hemostasis Trial) by Wong, S. Chiu et al.
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bjectives This trial compared the performance of a novel bioabsorbable vascular closure device
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us trans-femoral coronary or peripheral procedures.
ackground From a patient’s perspective, access site management after percutaneous procedures
emains challenging.
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atient died or suffered a major access-site-related adverse event. Minor adverse events were few among
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onclusions After 6-F percutaneous invasive procedures, TTH and TTA were both signiﬁcantly
horter in patients assigned to VCD than in patients managed with MC. The 30-day rates of access-
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786rom a patient’s perspective, access site discomfort during
heath removal and periprocedural immobilization are some
f the more exacting aspects of percutaneous vascular
rocedures. This has prompted the research and develop-
ent of vascular closure devices (VCDs) to minimize
iscomfort and shorten the time to ambulation (TTA) after
heath removal, without compromising safety compared
ith traditional manual compression (MC).
In the past decade, a variety of VCDs have become
vailable to facilitate the management of access sites after
ercutaneous vascular interventions (1). It was estimated
hat in 2007 VCDs were used to achieve hemostasis at the
ccess site in approximately 30% of the nearly 10 million
ercutaneous vascular procedures performed in the U.S. (2).
hile most devices currently approved by the U.S. Food
nd Drug Administration have been associated, in mul-
icenter randomized studies, with significantly shorter
ime to hemostasis (TTH) and TTA compared with
tandard manual or mechanical compression, their ease of
se, patient comfort during deployment, and safety pro-
les are inconsistent.
The ExoSeal VCD (Cordis
Corporation, Miami Lakes, Flor-
ida) was designed in an attempt to
potentially address some of these
deficiencies, and the ECLIPSE
(Ensure’s Vascular Closure De-
vice Speeds Hemostasis Trial)
study was carried out to compare
its safety and effectiveness with
that of MC in the promotion of
hemostasis and early ambulation
in patients undergoing percutane-
us arterial, diagnostic, or interventional procedures.
ethods
he ECLIPSE trial was a randomized, nonblinded trial,
onducted at 17 U.S. medical centers. Patients between 18
nd 85 years of age, scheduled to undergo a diagnostic or
nterventional coronary or peripheral procedure, via arterial
uncture of a 5-mm lumen diameter common femoral
rtery, using a standard 6-F, 11-cm long introducer
heath, were eligible for enrollment in the trial. Patients
ere excluded from the trial if they: 1) had sustained a
yocardial infarction with ST-segment elevation 48 h
efore the catheterization procedure; 2) had uncontrolled
ypertension at time of closure (blood pressure 180/110
m Hg); 3) had symptomatic leg ischemia in the target
essel limb, or had undergone prior femoral vascular surgery
r placement of a vascular graft at the target site; 4) had a
istory of bleeding or platelet disorder, or had been treated
ith a thrombin-specific anticoagulant or low-molecular-
bbreviations
nd Acronyms
I  confidence interval
AE  major adverse event
C  manual compression
TA  time to ambulation
TH  time to hemostasis
CD  vascular closure
eviceeight heparin 24 h before the catheterization procedure, 4r were heparinized and: a) were assigned to VCD and had
250 s pre-closure activated clotting time in presence, or
300 s in absence of a glycoprotein IIb/IIIa inhibitor, or b)
ere assigned to MC and had a 180 s pre-closure
ctivated clotting time; 5) required punctures of both
emoral arteries; 6) had undergone prior closure of the target
rtery with any VCD or MC 30 days before the cathe-
erization procedure; 7) had fluroscopically visible calcium,
therosclerotic disease, or stent 1 cm of the puncture site
hat would interfere with VCD plug placement; or 8) had a
re-existing systemic or cutaneous infection.
evice description. The ExoSeal VCD is a novel bioabsorb-
ble device designed for the sealing of femoral artery
uncture sites in patients who have undergone diagnostic or
nterventional procedures using a standard 6-F introducer
heath. The device achieves hemostasis by means of a
isually guided deployment mechanism that delivers a bio-
bsorbable poly-glycolic acid “plug” atop the femoral artery,
nchored by the neurovascular bundle sheath. The plug,
hich is entirely extravascular, is subsequently hydrolyzed
nto CO2 and H2O via the Kreb’s cycle, over a 3-month
eriod.
tudy end points. The primary efficacy end points of the study
ere: 1) TTH, measured in minutes; and 2) TTA, mea-
ured in hours. Hemostasis was defined as no or minimal
ubcutaneous oozing and the absence of expanding or
eveloping hematoma. TTH was measured from the time
he introducer sheath was removed to the time hemostasis
as achieved. TTA was defined as time the introducer
heath was removed to the time the patient was able to stand
nd walk 20 ft, without recurrence of bleeding. Patients
ot receiving glycoprotein IIb/IIIa inhibitors treated with
he VCD were to first be evaluated for ambulation at 1 h
ost-hemostasis; similar patients treated with MC were to
rst be evaluated no later than 4 h, and thereafter as
linically indicated. Patients receiving glycoprotein IIb/IIIa
nhibitors were to first be evaluated at 2 and 6 h, respec-
ively. While patients were recommended to have their
mbulatory status evaluated at the aforementioned times,
mbulation was not required if contrary to the clinical
udgment of the physician.
The secondary efficacy end points of the study were: 1)
ime-to-eligibility for hospital discharge, measured from the
ime of access site closure to the time when the patient was
udged by the physician to be ready for discharge from the
ospital; 2) time-to-hospital discharge, measured from the
ime of access site closure to the time of patient discharge;
) procedure success, defined as hemostasis achieved by the
ssigned method, without occurrence of a closure-related
ajor adverse event (MAE). A MAE was defined as: 1)
eed for vascular repair by surgical or nonsurgical tech-
iques; 2) bleeding requiring a blood transfusion; 3) infec-
ion requiring antibiotics, extended hospitalization, or both;
) new onset ischemia of the ipsilateral lower extremity; 5)
n
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787eed for surgical repair of access-site-related nerve injury; or
) permanent access site-related nerve injury. Device success
as defined as: 1) the uncomplicated deployment of the
lug; 2) hemostasis achieved in 5 min; and 3) removal of
n intact delivery system.
The primary safety end point was the 30-day rate of
ombined arterial closure-related MAE. The secondary safety
nd points included multiple fatal or nonfatal post-
rocedural complications including: 1) recurrent local
leeding requiring a hemostatic intervention, or a 6-cm
ematoma or ecchymosis; 2) development of pseudoaneu-
ysm, arterio-venous fistula, vascular laceration, or retroper-
toneal bleeding; 3) ipsilateral manifestations of vascular
nsufficiency or embolization, including loss of distal pulse,
otal arterial occlusion, or deep vein thrombosis; 4) infec-
ion; and 5) nerve injury.
tudy protocol and data collection. The ECLIPSE study
rotocol was reviewed and approved by the institutional
eview committee of each participating medical institution,
nd all patients granted their informed consent to be
ncluded in the trial.
ANDOMIZATION PROCEDURE. At the completion of diagnostic or
nterventional procedures, femoral angiograms were ob-
ained. Patients were then randomly assigned to VCD
ersus MC, using sealed envelopes in a 2:1 design favoring
he VCD. The assignment was based on a computer-
enerated treatment list, which balanced the randomization
y center and by type of procedure performed (coronary
ersus peripheral, and diagnostic versus interventional). An
nrollment of at least 400 randomly assigned patients was
lanned, with at least 50% of patients undergoing an
nterventional procedure. In addition, a series of “roll-in”
atients, treated with VCDs during the training period of
ach participating institution and not randomized, was
ncluded in a planned separate data collection and analysis.
The enrollment period of the trial lasted 6 months, and the
atient clinical follow-up lasted 30 days. The data were
ollected by clinical coordinators at the clinical sites, and were
anaged and analyzed by an independent clinical research
rganization (Averion International Corp., Southborough,
assachusetts). Detailed information regarding the catheter-
zation procedure, including the time from insertion of the
rocedural sheath to completion of the procedure and removal
f procedural catheters, was recorded. A baseline duplex
ltrasound examination of the target femoral artery closure site
as performed before the index procedure in the first 25% of
he overall sample population. After the procedure was com-
leted, a femoral angiogram was performed and the activated
lotting time was measured. At that point, if all the criteria for
ntry in the trial were satisfied, an envelope was opened to
andomly assign the patient to VCD or MC stratified accord-
ng to the type of procedure, interventional versus diagnostic,
erformed. bAfter the vessel closure procedure was completed, imme-
iate effectiveness and safety end points were ascertained.
ll relevant adverse events were recorded, including recur-
ence of bleeding at the procedural site, which was treated
y MC or other techniques to achieve hemostasis. On the
ay of discharge from the hospital, or on the day the patient
as judged by the investigator to be ready for discharge
rom the hospital, a detailed assessment of medications,
edal pulse score, interim adverse events, and secondary
afety measures was performed, and the access site was
losely examined for abnormalities such as ecchymosis,
welling, mass, infection, or bruit.
OLLOW-UP VISIT. Patients were scheduled to return for a
ollow-up visit (30-day visit) no earlier than 23 and no later
han 37 days after the index procedure. At that time, the
atient’s interim medical history, clinical status, pedal pulse
core, and occurrence of adverse events since hospital
ischarge were recorded. The access site was examined for
bnormalities such as ecchymosis, swelling, mass, infection,
r bruit. In addition, patients who had been selected for a
aseline duplex ultrasound of the vascular access site under-
ent repeat ultrasound studies at the 30-day visit.
rocedural anticoagulation. The anticoagulation regimens
rescribed in each study subgroup before, during, and after
he index procedure were left to the discretion of each
ndividual investigator. The numbers and percentages of
atients treated with abciximab, aspirin, clopidogrel,
ptifibatide, and heparin in each study group are shown
n Table 1. It is noteworthy that in the groups assigned to
CD and MC, heparin was administered respectively to
4.7% and 94.1% of patients during interventional pro-
edures, versus only 7.5% and 6.1% of patients during
iagnostic procedures.
tudy monitoring. An independent Clinical Events Com-
ittee (Online Appendix) adjudicated significant clinical
vents, and an independent Data and Safety Monitoring
ommittee (Online Appendix) reviewed the reported ad-
erse events throughout the trial.
tatistical analyses. The data were analyzed on the intention-
o-treat principle. The randomly assigned patient groups were
nalyzed separately from the “roll-in” group. For the effective-
ess analysis, a sequential testing procedure was implemented,
hich assessed TTH first, followed by TTA if statistical
ignificance was reached in the analysis of TTH. An unpaired
test with a 5% 2-sided type I error rate was used in both
nalyses. After confirming the statistical significance of the
ifferences in both primary effectiveness end points between
he randomly assigned groups, a noninferiority test with a 5%
-sided type I error rate was applied to the primary safety end
oint of composite 30-day MAE, using a pre-specified non-
nferiority margin of 4%. The noninferiority p value was
alculated using Cytel StatXact, version 6.0 (Cytel Inc., Cam-
ridge, Massachusetts).
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788Besides the primary end points, the baseline patients and
rocedural characteristics and miscellaneous end points
ere also described, with calculations of means and standard
eviation for continuous variables, and frequencies (in
ercentages) for categorical variables. When comparing
roups assigned to VCD versus MC, Wilcoxon rank sum
est and t test were applied for continuous and ordinal
ariables, and Fisher exact test for binary variables. Differ-
nces between 2 groups and 95% confidence intervals (CIs)
f the differences were calculated. Statistical significance was
eclared when the 2-sided p value was 0.05. All statistical
nalyses were performed using the SAS statistical software,
ersion 8.2 (SAS Institute, Cary, North Carolina) unless
pecified otherwise.
esults
etween February 2007 and August 2007, 401 patients were
andomly assigned to either VCD (n  267) or MC (n 
34), and 87 patients were included in the ECLIPSE trial
Table 1. Baseline Patient and Procedure Characteristics of the 3 Study Gr
Rol
(n 
Patient characteristics
Age, yrs 63.3
Women, n (%) 29 (3
Body mass index 30 kg/m2, n (%) 41 (4
Baseline hematocrit, % 40.4
History of: n (%) of patients
Percutaneous coronary intervention 37 (4
Coronary artery bypass graft 16 (1
Peripheral vascular surgery or graft 4 (4
Hyperlipidemia 70 (8
Hypertension 70 (8
Diabetes 21 (2
Renal insufﬁciency 7 (8
Smoking 39 (4
Systolic blood pressure,* mm Hg 134
Procedure characteristics
Type of procedure, n (%) of patients
Diagnostic 58 (6
Interventional 29 (3
Antithrombotic treatment, n (%) of patients†
Abciximab 2 (2
Aspirin 2 (2
Clopidogrel 7 (8
Eptiﬁbatide 9 (1
Heparin 37 (4
Activated clotting time,* s 168
Unless specified otherwise, values aremean SD. *Immediately before sheath removal; †among pa
in the manual compression (MC) and vessel closure device (VCD) groups received eptifibatide; ‡
nonsignificant.s “roll-ins.” Of the 401 randomly assigned patients, 200 p50%) underwent diagnostic and 201 underwent interven-
ional procedures. The baseline demographic and clinical
haracteristics of the 3 study groups were similar (Table 1).
he mean ages of the patients in the VCD, MC, and
roll-in” groups were 63.3  11.1 years, 61.4  10.5 years,
nd 63  11.6 years, respectively (p  NS). Approximately
wo-thirds of patients in each group were men. The body
ass index was 30 and 40 kg/m2 in 37.4%, 33.6%, and
7.1% of patients in the VCD, MC, and “roll-in” groups,
espectively (p  NS).
ffectiveness analysis. Procedural success, defined as hemo-
tasis achieved by the assigned method without occurrence
f a closure-related MAE on the day of procedure and at 30
ays, was achieved in 245 of 267 patients (91.8%) assigned
o VCD versus 122 of 134 patients (91%) assigned to MC
p  NS), and in 83 “roll-in” patients (95.4%). Device
uccess, defined as uncomplicated deployment of the plug,
emoval of an intact delivery system, and hemostasis
chieved in 5 min, was observed in 238 patients assigned
o VCD (89.1%) and 83 “roll-in” patients (95.4%). In
VCD
(n  267)
MC
(n  134)
63.3 11.1 61.4 10.5
85 (32) 51 (38)
100 (37.4) 45 (33.6)
41.4 2.0 40.5 4.4
110 (41.2) 61 (45.5)
45 (16.9) 24 (17.9)
8 (3.0) 1 (0.8)
211 (79.0) 117 (87.3)
206 (77.2) 98 (73.1)
68 (25.5) 44 (32.8)
23 (8.6) 9 (6.7)
152 (57.1) 66 (49.3)
133 20 133 20
134 (50.2) 66 (49.3)
133 (49.8) 68 (50.8)
10 (7.5) 4 (5.9)
7 (5.3) 3 (4.4)
28 (21.1) 12 (17.6)
27 (10.1) 11 (8.2)
136 (50.9) 68 (50.7)
181 56 142 34‡
ho underwent diagnostic procedures, none received abciximab or clopidogrel, and 1 patient each
001 versus VCD; all other differences between the 2 randomly assigned groups are statisticallyoups
l-In
87)
11.6
3)
7.1)
4.2
2.5)
8.4)
.6)
0.5)
0.5)
4.1)
.1)
4.8)
22
6.7)
3.3)
.3)
.3)
.0)
0.3)
2.5)
55
tients w
p  0.0atients considered to have device failures, achievement of
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789emostasis was5 min in all patients, and plug deployment
as unsuccessful in 21 of 33 patients. None of these patients
uffered any closure-related MAE; however, 2 failures
esulted in rebleeding at the site, 2 in hematomas  6 cm,
nd 1 patient had an asymptomatic decrease in pedal pulse
rom grade 2 to 1.
The primary effectiveness end points could be evaluated
n all 401 randomly assigned patients (Table 2). The mean
TH was 4.4  11.6 min in the group assigned to VCD
ersus 20.1  22.5 min in the group assigned to MC,
orresponding to a 15.7 min difference (95% CI: 19.0 to
2.3; p  0.0001). Likewise, TTA was significantly shorter
n the group assigned to VCD (2.5  5.0 h) than in the
roup assigned to MC (6.2  13.3 h) corresponding to a
.7 h difference (95% CI: 5.5 to 1.9; p  0.0028).
Among the 401 randomly assigned patients, 200 under-
ent diagnostic and 201 underwent interventional proce-
ures. Among the 200 patients who underwent diagnostic
rocedures, 134 were randomly assigned to VCD and 66 to
C. In addition, 58 “roll-in” patients underwent diagnostic
rocedures. Among the 201 randomly assigned patients
ho underwent interventional procedures, 133 were as-
igned to VCD and 68 to MC; interventional procedures
ere also performed in 29 “roll-in” patients. Table 3 shows
he results of the primary effectiveness end points in these
atient subgroups. As in the case of the overall population,
oth TTH and TTA were significantly shorter in patients
Table 2. Effectiveness and Safety Results in the 3 Study Groups
Roll-Ins
(n  87) (n
Effectiveness measures
Time to (mean  SD)
Hemostasis (min) 4.7 19.4 4.4
Ambulation (h) 2.0 2.6 2.5
Eligibility for hospital discharge (h) 9.7 14.2 (n 85) 12.6
Hospital discharge (h) 13.6 18.5 16.8
Device deployment (min) 0.9 1.1 1.0
Safety measures to 30 days (n  84) (n
Major adverse events composite† 0
Secondary safety composite end point 7 (8.3)
Rebleeding after initial hemostasis 3 (3.6)
Access site hematoma 6 cm 3 (3.6)
Access site-related bleeding requiring
30 min for hemostasis
1 (1.2)
Transient access site-related nerve injury 0
Retroperitoneal bleeding 0
Ecchymosis 6 cm 1 (1.2)
Decreased pedal pulse 1 (1.2)
Death 0
Unless specified otherwise, values indicate n (%) of patients. *The p value for primary safety end p
margin of 4.0%. The p values for the secondary end points were from Fisher exact test; †primary safe
requiring transfusion, b) infection requiring antibiotics or extended hospitalization, c) nerve injury rCI confidence interval; other abbreviations as in Table 1.ssigned to VCD than in patients assigned to MC regard-
ess whether patients underwent diagnostic or interventional
rocedures. While in the group assigned to MC, the mean
TH was significantly longer among patients who under-
ent interventional than among patients who underwent
iagnostic procedures (25.2  30.5 min vs. 14.8  5.9 min,
 0.008), this difference was not significant in the group
ssigned to VCD (5.4  15.6 min vs. 3.3  4.9 min, p 
.143). Figure 1 compares the mean TTH and TTA
etween patients assigned to VCD and patients assigned to
C, who were treated with glycoprotein IIb/IIIa receptor
lockers during the procedures. Both times were signifi-
antly shorter in the group assigned to VCD.
tudy compliance and safety end points. Clinical follow-up
as available at 30 days visit in 256 (95.9%), 126 (94.0%),
nd 84 (96.6%) patients assigned to VCD and MC, and in
he “roll-in” group, respectively. No patient, in any group,
ied during the trial or experienced an arterial closure-
elated MAE, confirming the study hypothesis of noninfe-
iority of the VCD compared with MC with respect to the
rimary safety end point. A few secondary safety adverse
vents occurred in each study group, without statistically
ignificant differences among the groups or between the
ubgroups of patients who underwent diagnostic versus
nterventional procedures (Tables 2 and 3). Rebleeding after
nitial hemostasis (n  17 of 382) and access site hematoma
6 cm (n 7 of 382) were the most frequent adverse events
7)
MC
(n  134)
VCD-MC
(95% CI) p Value*
20.1 22.5 (n 131) 15.7 (19.0 to12.3) 0.0001
 264) 6.2 13.3 (n 129) 3.7 (5.5 to1.9) 0.0028
 257) 16.3 27.5 (n 128) 3.7 (7.8 to 0.5) 0.1540
 264) 19.4 29.2 (n 133) 2.6 (7.5 to 2.3) 0.3612
 260) — — —
6) (n  126)
0 0 (0 to 1.05) 0.0005
) 5 (4.0) 4.6 (1.1 to 9.2) 0.1360
) 3 (2.4) 3.1 (1.8 to 6.9) 0.1989
1 (0.8) 1.6 (2.2 to 4.3) 0.4334
1 (0.8) 0.4 (4.0 to 1.5) 0.5503
0 0.4 (2.6 to 2.2) 1.0000
0 0.8 (2.2 to 2.8) 0.3298
1 (0.8) 0.8 (4.4 to 0.8) —
0 — —
0 — —
s calculated from the noninferiority test between VCD and MC with a pre-specified noninferiority
point includes: 1) need for surgical or nonsurgical vascular repair; 2) access site-related: a) bleeding
g surgery, d)30 days nerve injury; and 3) new ipsilateral lower extremity ischemia.VCD
 26
11.6
5.0 (n
13.9 (n
19.8 (n
2.1 (n
 25
0
22 (8.5
14 (5.4
6(2.4)
1 (0.4)
1 (0.4)
2 (0.8)
0
0
0
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790bserved in both the randomized VCD and the MC groups.
wo patients who underwent interventional procedures in
he VCD group suffered from retroperitoneal bleeding
ocumented by computed tomography scan. One patient
xperienced transient decrease in blood pressure after device
eployment and responded promptly with fluid without
ransfusion. His hematocrit decreased from 43.7% to 32.1%.
Table 3. Effectiveness and Safety Results in the 3 Study Subgroups Stratifi
Effectiveness Measures Roll-Ins V
Diagnostic procedures (n  58) (n 
Time to (mean SD)
Hemostasis (min) 2.7 2.8 3.3 4.9
Ambulation (h) 1.4 0.8 1.6 1.2
Eligibility for hospital discharge (h) 5.4 14.8 (n 57) 4.9 7.4
Hospital discharge (h) 9.7 21.4 8.7 20
Device deployment (min) 1.0 1.3 1.2 2.9
30-day major adverse events
composite†
0
Interventional procedures (n  29) (n 
Time to (mean  SD)
Hemostasis (min) 8.6 33.4 5.4 15
Ambulation (h) 3.10 4.17 3.5 6.9
Eligibility for hospital discharge (h) 18.4 6.9 (n 28) 20.5 14
Hospital discharge (h) 21.6 5.1 24.8 15
Device deployment (min) 0.9 0.8 0.8 0.8
30-day major adverse events
composite†
0
Unless specified otherwise, values indicate numbers (%) of patients. *The p value for the primary
noninferiority margin of 4.0%; †primary safety end point includes: 1) need for surgical or nonsurgic
or extended hospitalization, c) nerve injury requiring surgery, d)30 days nerve injury; and 3) new
CI confidence interval; other abbreviations as in Table 1.
Figure 1. TTH and TTA in Patients Treated With Glycoprotein IIb/IIIa Rece
In the subgroup of patients who received glycoprotein IIb/IIIa receptor blocker
to hemostasis (TTH) (left) and time to ambulation (TTA) (right) in patients ass
compression (MC).second patient complained of groin discomfort 2 h after
he procedure, and a small localized swelling was noted on
outine groin evaluation. His hematocrit dropped from
3.6% to 25.4%. Neither patient had documented back
ain, prolonged hypotension, required a blood transfusion
r vascular repair. The first patient was discharged 28 h and
he second at 96 h after the procedure.
Diagnostic Versus Interventional Procedure
MC VCD-MC (95% CI) p Value*
(n  66)
14.8 5.9 (n 65) 11.5 (13.0 to9.9) 0.0001
33) 6.6 18.4 5.0 (8.2 to1.9) 0.0295
31) 11.9 35.4 (n 64) 7.0 (13.3 to0.6) 0.1257
132) 14.8 38.8 (n 65) 6.1 (14.3 to 2.2) 0.2402
31) — — —
0 0 (0 to 1.99) 0.0091
(n  68)
25.2 30.5 (n 66) 19.8 (26.2 to13.4) 0.0001
31) 5.8 3.5 (n 63) 2.3 (4.1 to0.5) 0.0022
126) 20.6 15.2 (n 64) 0.2 (4.7 to 4.3) 0.9460
132) 23.7 14.4 1.1 (3.4 to 5.6) 0.6270
29) — — —
0 0 (0 to 2.00) 0.0093
end point was calculated from the noninferiority test between VCD and MC with a pre-specified
lar repair; 2) access site-related: a) bleeding requiring transfusion, b) infection requiring antibiotics
ral lower extremity ischemia.
locker
g their procedures, there was a signiﬁcant reduction in both the mean time
vessel closure device (VCD) compared with patients assigned to manualed by
CD
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791uplex ultrasonographic observations. Pre-procedural du-
lex ultrasound of the target femoral artery was obtained in
7 patients assigned to VCD and 33 patients assigned to
C. The studies were technically satisfactory in 98.5% and
00% of patients, respectively. Turbulent blood flow or
igns of partial vascular obstruction were observed in 4
atients (6.0%) in the VCD group and 2 patients (6.1%) in
he MC group before index procedure. The duplex ultra-
ound studies were repeated at the 30-day visit in 62
atients in the VCD group and 32 patients in the MC
roup, and were technically satisfactory in 100% of patients.
urbulent blood flow or signs of partial vascular obstruction
ere observed in 4 patients (6.5%) in the VCD group and
patient (3.1%) in the MC group. The patients with
ollow-up ultrasound abnormalities were not the same as
hose with abnormal baseline studies. These between-group
ifferences were all statistically nonsignificant. It is partic-
larly noteworthy that no pseudo-aneurysm, arterio-venous
stula, or hematoma was observed on 30-day follow-up
ltrasound examination in either study group.
iscussion
mpetus for the development of VCDs. In patients undergo-
ng diagnostic or interventional procedures, all currently
vailable VCDs shorten TTH and TTA significantly when
ompared with MC. This effect is generally beneficial,
articularly in patients presenting with chronic back pain,
ongestive heart failure, prostate enlargement, mental im-
airment, or other disorders that preclude prolonged bed
est after the procedure.
Despite substantial improvements in device design and
ains in operator experience over the past decade, VCDs
ere deployed in only 30% of the estimated 10 million
ercutaneous vascular procedures performed in the U.S. in
007 (2). This underutilization of VCDs for the manage-
ent of access site hemostasis after percutaneous procedures
s clearly multifactorial, including costs of materials, ease of
se, and lack of definitive evidence that VCDs are at least as
afe as MC when applied to a variety of anatomical sites and
linical states.
afety of current VCDs. Since VCDs are often deployed in
ully anticoagulated patients after percutaneous interven-
ional procedures, bleeding complications in these patients
re potentially more serious than with MC, where removal
f the sheath is usually postponed until normal clotting
tatus has returned. In recent analyses and meta-analyses of
ingle- and multicenter clinical trials, bleeding complica-
ions associated with percutaneous interventions were not
nly costly (3), but also a predictor of poor prognosis and
ncreased short- and long-term mortality (4–9).
Concerns regarding the safety of VCDs have prompted 2
onsecutive U.S. Food and Drug Administration reviews,
sing the American College of Cardiology–National Car- uiovascular Data Registry (10,11). The combined results of
oth studies suggest that the overall safety in patients
reated with VCDs and MC is similar, with the exception of
greater risk of major local vascular complications after
ardiac catheterization observed with the VasoSeal device
Datascope Corp., Montvale, New Jersey) (11). In a meta-
nalysis of 16 randomized clinical studies comparing the
ates of access site complications (excluding hematoma)
ssociated with VCDs versus MC in over 5,000 patients,
aitkus (12) reported a lower risk of vascular complications
ssociated with VCD. As was confirmed by Tavris et al.
11), the VasoSeal VCD performed less well than other
evices. Two other meta-analyses comparing the safety of
CD with MC, published in 2004 (13,14), found similar
ates of periprocedural, access site complication with VCD
nd MC, whether the procedure was diagnostic or inter-
entional. Furthermore, in the meta-analysis by Nikolsky et
l. (14), the overall complication rate in the setting of
nterventional procedures was significantly higher with the
asoSeal VCD than with MC. Finally, in the meta-analysis
y Koreny et al. (13), as in this study, TTH was significantly
horter with the use of VCD than when MC was applied.
In 2002, Applegate et al. (15) observed lower rates of
ascular complications than reported in the previous decade,
hich they attributed, among other factors, to less vigorous
ntithrombotic therapy and greater operator experience.
ther single-center studies have confirmed the effectiveness
f access site management with VCD, including in higher
isk subgroups, such as women (16) and patients treated
ith glycoprotein IIb/IIIa inhibitors (17). In addition, in a
ery recent analysis of a prospective registry, which enrolled
early 13,000 consecutive patients in the years 2002 through
007, Arora et al. (18) found significantly lower rates of
ascular complications with the use of VCD than with MC
n “appropriately selected patients undergoing diagnostic
nd therapeutic cardiac catheterizations.” Furthermore, us-
ng a second-order Monte Carlo simulation model, Resnic
t al. (3) found that the routine use of a VCD was more cost
ffective than MC in a recent case-control analysis of nearly
,000 patients who underwent percutaneous coronary inter-
entions.
he ExoSeal device. Currently available VCDs could cer-
ainly be further improved. The device used in this study has
everal favorable design characteristics. In particular, the
oly-glycolic acid material that constitutes the “felt like”
lug is synthetic, eliminating the potential adverse effect(s)
ssociated with animal-based components. Once deployed,
he hemostatic plug is entirely extravascular, with no intra-
ascular components. It is completely absorbed within 3
onths through a noninflammatory hydrolysis process via
he Kreb’s cycle, which might: 1) lessen scarring of the
ccess site; 2) enhance the safety of its use; and 3) facilitate
ubsequent re-entries at the same access site. The device
ses the existing arterial sheath as the conduit for its
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792eployment, minimizing the need for widening of the track
hrough the tissues, and eliminating maneuvers that may
ause discomfort at the femoral access site during its
eployment. In contrast to all currently available VCD, the
eployment of this device depends mostly on visual rather
han on tactile cues. The unique, visually guided deploy-
ent mechanism eliminates the obligatory push and tug
teps, which are usually associated with greater patient
iscomfort.
he ECLIPSE trial. This trial showed that the study device
as effective when used in patients undergoing coronary or
eripheral, diagnostic or interventional procedures, using
-F instrumentation. No major access site complication was
bserved in either study group, and the device was deployed
ithin approximately 1 min. Compared with MC, TTH
nd TTA were markedly shorter in patients treated with the
CD, despite the performance of percutaneous coronary
nterventions in nearly 50% of patients, and the intraproce-
ural administration of glycoprotein IIb/IIIa inhibitors in
ver 10% of patients. In patients who underwent diagnostic
rocedures and were randomly assigned to VCD, in contrast
ith MC, no significant difference in TTH was observed
etween patients who underwent diagnostic and interven-
ional procedures.
Retroperitoneal hemorrhages occurred in 2 patients who
ad undergone interventional procedures in the VCD
roup. Neither patient required surgical or percutaneous
nterventions, or blood transfusions. Whether the rate of
econdary complications associated with the use of VCD
bserved in this trial will decrease overtime with more
efined operator experience remains to be determined.
tudy limitations. As mandated by the protocol, patients
ith femoral arterial disease, moderate calcifications at the
ite of sheath insertion, or whose femoral artery was
annulated within the prior 30 days were excluded from the
rial. Therefore, the performance of this VCD in these more
real-world” clinical settings still needs to be studied and
ompared with that of other currently available devices.
Despite the roll-in patients, the total number of patients
nrolled per site is relatively small minimizing the benefit of
learning curve with this VCD technique. In addition,
atient satisfaction and cost effectiveness of ExoSeal com-
ared with MC and other VCDs was not examined in the
urrent study. Future clinical studies to further assess
hether the design advantages of ExoSeal, with its extravas-
ular noninflammatory plug and unique visually guided
eployment mechanism, will translate into significant im-
rovements in clinical outcomes over the currently available
CDs are clearly warranted.
onclusions
n this study of patients at standard risk for the use of a
CD, the ExoSeal device after interventional or diagnostic
1rocedures with 6-F instrumentation in coronary and pe-
ipheral vessels was associated with a marked shortening of
TH and TTA, and with rates of access site complications
imilar to those observed with MC. No major complication
as observed during the trial in any study group. Follow-up
ltrasound examinations performed at 30 days in 25% of the
ample population revealed no abnormality at the access
ite.
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